一名阿哌沙班和利伐沙班治疗失败的患者可能存在因子 Xa 抗药性

IF 0.6 Q3 MEDICINE, GENERAL & INTERNAL Clinical Case Reports Pub Date : 2024-11-26 DOI:10.1002/ccr3.9623
Ola Ali, Awab Elnaeem, Manmeet Kaur, Nitisha Thatikonda, Julia Aigbogun, A. K. M. Muktadir
{"title":"一名阿哌沙班和利伐沙班治疗失败的患者可能存在因子 Xa 抗药性","authors":"Ola Ali,&nbsp;Awab Elnaeem,&nbsp;Manmeet Kaur,&nbsp;Nitisha Thatikonda,&nbsp;Julia Aigbogun,&nbsp;A. K. M. Muktadir","doi":"10.1002/ccr3.9623","DOIUrl":null,"url":null,"abstract":"<p>This article aims to discuss the literature on switching to an anticoagulant with a different mechanism of action in case of treatment failure. We present a patient with atrial fibrillation who incurred an embolic stroke despite adequate anticoagulation with apixaban and developed a new symptomatic ischemic stroke during the same admission after switching to rivaroxaban, a factor Xa inhibitor with a similar mechanism of action. He had no new events at 3-months after switching to dabigatran, a direct thrombin inhibitor. We identified no apparent reason for anticoagulation failure in our patient. The literature on switching anticoagulants in case of failure is inconclusive with no strong supportive evidence. More research is needed to define anticoagulation failure and identify cases with factor Xa inhibitor resistance, in which switching to a different mechanism of anticoagulation may be appropriate.</p>","PeriodicalId":10327,"journal":{"name":"Clinical Case Reports","volume":"12 12","pages":""},"PeriodicalIF":0.6000,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ccr3.9623","citationCount":"0","resultStr":"{\"title\":\"Possible Factor Xa Resistance in a Patient Who Failed Apixaban and Rivaroxaban\",\"authors\":\"Ola Ali,&nbsp;Awab Elnaeem,&nbsp;Manmeet Kaur,&nbsp;Nitisha Thatikonda,&nbsp;Julia Aigbogun,&nbsp;A. K. M. Muktadir\",\"doi\":\"10.1002/ccr3.9623\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>This article aims to discuss the literature on switching to an anticoagulant with a different mechanism of action in case of treatment failure. We present a patient with atrial fibrillation who incurred an embolic stroke despite adequate anticoagulation with apixaban and developed a new symptomatic ischemic stroke during the same admission after switching to rivaroxaban, a factor Xa inhibitor with a similar mechanism of action. He had no new events at 3-months after switching to dabigatran, a direct thrombin inhibitor. We identified no apparent reason for anticoagulation failure in our patient. The literature on switching anticoagulants in case of failure is inconclusive with no strong supportive evidence. More research is needed to define anticoagulation failure and identify cases with factor Xa inhibitor resistance, in which switching to a different mechanism of anticoagulation may be appropriate.</p>\",\"PeriodicalId\":10327,\"journal\":{\"name\":\"Clinical Case Reports\",\"volume\":\"12 12\",\"pages\":\"\"},\"PeriodicalIF\":0.6000,\"publicationDate\":\"2024-11-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ccr3.9623\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Case Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/ccr3.9623\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ccr3.9623","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

本文旨在讨论在治疗失败的情况下改用作用机制不同的抗凝剂的文献。我们介绍了一名心房颤动患者,尽管他使用阿哌沙班进行了充分的抗凝治疗,但仍发生了栓塞性脑卒中,在改用具有类似作用机制的 Xa 因子抑制剂利伐沙班治疗后,他在入院的同一天又发生了新的症状性缺血性脑卒中。在改用达比加群(一种直接凝血酶抑制剂)3 个月后,他没有发生新的事件。我们没有发现患者抗凝失败的明显原因。关于在抗凝失败的情况下更换抗凝药物的文献尚无定论,也没有有力的支持证据。需要开展更多研究来定义抗凝失败,并确定 Xa 因子抑制剂耐药的病例,在这些病例中,换用不同的抗凝机制可能是合适的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Possible Factor Xa Resistance in a Patient Who Failed Apixaban and Rivaroxaban

This article aims to discuss the literature on switching to an anticoagulant with a different mechanism of action in case of treatment failure. We present a patient with atrial fibrillation who incurred an embolic stroke despite adequate anticoagulation with apixaban and developed a new symptomatic ischemic stroke during the same admission after switching to rivaroxaban, a factor Xa inhibitor with a similar mechanism of action. He had no new events at 3-months after switching to dabigatran, a direct thrombin inhibitor. We identified no apparent reason for anticoagulation failure in our patient. The literature on switching anticoagulants in case of failure is inconclusive with no strong supportive evidence. More research is needed to define anticoagulation failure and identify cases with factor Xa inhibitor resistance, in which switching to a different mechanism of anticoagulation may be appropriate.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Clinical Case Reports
Clinical Case Reports MEDICINE, GENERAL & INTERNAL-
自引率
14.30%
发文量
1268
审稿时长
13 weeks
期刊介绍: Clinical Case Reports is different from other case report journals. Our aim is to directly improve global health and increase clinical understanding using case reports to convey important best practice information. We welcome case reports from all areas of Medicine, Nursing, Dentistry, and Veterinary Science and may include: -Any clinical case or procedure which illustrates an important best practice teaching message -Any clinical case or procedure which illustrates the appropriate use of an important clinical guideline or systematic review. As well as: -The management of novel or very uncommon diseases -A common disease presenting in an uncommon way -An uncommon disease masquerading as something more common -Cases which expand understanding of disease pathogenesis -Cases where the teaching point is based on an error -Cases which allow us to re-think established medical lore -Unreported adverse effects of interventions (drug, procedural, or other).
期刊最新文献
Early Hints of Metagenome Next-Generation Sequencing and Copy Number Variations Analysis: An Occult Case of Leptomeningeal Metastasis With Rapid Cognitive Decline Large Myxoid Ovarian Leiomyoma: A Case Report An Unusual Case of Girl With Juvenile Idiopathic Arthritis Later Diagnosed With Systemic Lupus Erythematosus: Diagnostic Challenges in Pediatric Rheumatology Steroid-Induced Psychosis in a Child With Nephrotic Syndrome Secondary to Focal Segmental Glomerulosclerosis: A Case Report Anesthesia Management of Cold Agglutinin Disease in a Pregnant Patient: A Case Report
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1